Friday, March 22, 2024 3:04:14 PM
Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer, commented, “The participation in our private placement from five of our independent directors points to their confidence in the science and clinical pathways for our immuno-oncology therapies targeting difficult-to-treat cancers.”
Stan V. Smith, Ph.D., added, “I have participated in every round of financing and I am a big believer in MAIA’s telomere-targeting approach to cancer and its potential to disrupt the field of research and development for cancer therapies, for the benefit of all humankind.”
Dr. Smith is president of Smith Economics Group, Ltd. in Chicago, providing economic and financial consulting nationwide. Trained at the University of Chicago and specializing in litigation economics, Dr. Smith co-authored the first textbook on the subject of economic damages. Dr. Smith has served as an adjunct professor at the University of Chicago and at DePaul University College of Law where he created the first course in the United States in forensic economics.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
Recent MAIA News
- MAIA Biotechnology to Present at the BIO International Convention 2024 • Business Wire • 05/17/2024 12:37:00 PM
- MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting • Business Wire • 05/16/2024 12:37:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:07:15 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/15/2024 08:05:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:11:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 09:21:03 PM
- MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement • Business Wire • 04/30/2024 12:08:00 PM
- MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement • Business Wire • 04/29/2024 12:08:00 PM
- MAIA Biotechnology Announces $1.00 Million Private Placement • Business Wire • 04/23/2024 12:51:00 PM
- MAIA Biotechnology to Present at Two Investor Conferences in April 2024 • Business Wire • 04/05/2024 12:01:00 PM
- MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero • Business Wire • 03/28/2024 07:00:00 PM
- MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement • Business Wire • 03/26/2024 07:00:00 PM
- MAIA Biotechnology Announces $1.33 Million Private Placement • Business Wire • 03/26/2024 12:01:00 PM
- MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement • Business Wire • 03/22/2024 07:00:00 PM
- MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board • Business Wire • 03/21/2024 07:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:15:28 PM
- MAIA Biotechnology to Participate in the 36th Annual ROTH Conference • Business Wire • 03/07/2024 02:45:00 PM
- MAIA Biotechnology and Nationwide Children’s Hospital Announce Presentation of THIO’s Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting • Business Wire • 03/06/2024 04:04:00 PM
- MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients • Business Wire • 03/06/2024 01:48:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 01:00:38 PM
- MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders • Business Wire • 03/05/2024 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 10:23:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 09:17:06 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/14/2024 10:18:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 10:15:18 PM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter • HLYK • May 16, 2024 8:00 AM